Xiamen Amoytop Biotech Co., Ltd.   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Xiamen China (1994)
Status: No NME R&D (1994)

Organization Overview

First Clinical Trial
2009
NCT01232504
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Xiamen Amoytop Biotech Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dwarfism, Pituitary (Phase 3)

Endocrine System Diseases (Phase 3)

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis B (Phase 3)

Hepatitis B, Chronic (Phase 3)

Hepatitis C (Phase 3)

Hepatitis C, Chronic (Phase 3)

Hepatitis, Chronic (Phase 3)

Mycoses (Phase 4)

Neoplasms (Phase 3)

Neutropenia (Phase 2)

Pancytopenia (Phase 4)

Thrombocytopenia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 20
  • # of Trial APIs: 11